US9206258B2ActiveUtilityPatentIndex 52
Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same
Est. expiryDec 16, 2029(~3.5 yrs left)· nominal 20-yr term from priority
C07K 2317/732C07K 2317/73A61P 35/00C07K 16/3069C07K 2317/734A61P 35/04G01N 33/57557G01N 33/57555G01N 33/57407G01N 33/57434
52
PatentIndex Score
0
Cited by
29
References
1
Claims
Abstract
Disclosed herein are antibodies that detect a lipid-like antigen on prostate cancer cells and methods of detecting and treating prostate cancer using the same.
Claims
exact text as granted — not AI-modifiedWhat is claimed:
1. A method of preferentially inducing cell death in primary or metastatic prostate cancer cells that express PCLA over non-cancerous prostate cells in a human, comprising administering an anti-PCLA antibody having a variable light chain sequence as set forth in SEQ ID NO: 1 and a variable heavy chain sequence as set forth in SEQ ID NO :4, wherein the anti-PCLA antibody is capable of inducing ADCC and/or CDC.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.